Cumulatively, this data suggests that pro‐survival isoform switching of BCL2 family members together with DFFB isoform regulation may play a role in leukemia proliferation and survival and thus a potential therapeutic option with a pharmacological splicing modulatory compound. The gene discussed is BCL2; the disease is leukemia.